ArticleEJNMMI research2026
Optimal acquisition time of [
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04561492 (Exploratory Study Evaluating the Relevance of [68Ga]Ga -PentixaFor for Initial Staging and Therapeutic Evaluation of Symptomatic Multiple Myeloma Patients in First Line Treatment or in Relapse), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploratory Study Evaluating the Relevance of [68Ga]Ga -PentixaFor for Initial Staging and Therapeutic Evaluation of Symptomatic Multiple Myeloma Patients in First Line Treatment or in Relapse
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
background[68Ga]Ga-PentixaFor, a CXCR4-targeted PET tracer, has shown potential in multiple myeloma. However, [68Ga]Ga-PentixaFor-PET/CT acquisition protocols lack standardization. This is a prospective ancillary study to the PentiMyelo trial aimed to determine the optimal acquisition time for [68Ga]Ga-PentixaFor-PET.
resultsTwenty multiple myeloma patients underwent [68Ga]Ga-PentixaFor-PET/CT at 60 min post-injection, with additional acquisitions at 30, 40, 50 min (Group 1) or 75, 85, 95 min (Group 2). Semi-quantitative metrics including SUV, tumor-to-background ratios and image noise — assessed by the coefficient of variation, were systematically analyzed. Physiological liver, spleen and mediastinal blood-pool uptakes decreased over time while image noise increased. A total of 343 lesions were detected (316 in Group 1, 27 in Group 2). Neither earlier nor later acquisition time affected the positivity of [68Ga]Ga-PentixaFor-PET, which was positive in 10 of 20 patients (5 in Group 1 and 5 in Group 2). In Group 1, tumor-to-background ratio was significantly higher at 60 min; in Group 2, tumor-to-background ratio remained stable.
conclusionsAn acquisition time of 60 min post-injection provided optimal lesion contrast, supporting its adoption as the standard imaging time point for [68Ga]Ga-PentixaFor-PET/CT.
trial registrationName of the registry: ClinicalTrials.gov. Trial registration number: NCT04561492. Date of registration: 17 September 2020. URL of trial registry record: https://clinicaltrials.gov/study/NCT04561492 . This imaging sub-study is ancillary to the PentiMyelo prospective trial registered under the identifier NCT04561492.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.